Xiaojing Michael Wang

USPTO Granted Patents = 11 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 9.2

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

Novartis Vaccines & Diagnostics, Gmbh

patents

Years Active: 2001-2024

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12071441 - 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza (2024-08-27),

2. 11629149 - 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza (2023-04-18),

3. 11072610 - Antiviral pyridopyrazinedione compounds (2021-07-27),

4. 10660888 - Aminoheteroaryl benzamides as kinase inhibitors (2020-05-26),

5. 10188649 - Aminoheteroaryl benzamides as kinase inhibitors (2019-01-29),

6. 10160726 - Quinolone derivatives as antibacterials (2018-12-25),

7. 9763937 - Aminoheteroaryl benzamides as kinase inhibitors (2017-09-19),

8. 9242996 - Aminoheteroaryl benzamides as kinase inhibitors (2016-01-26),

9. 7470701 - Substituted 2,5-heterocyclic derivatives (2008-12-30),

10. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia (2002-11-26),

11. 6180629 - [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia (2001-01-30),

Certainly! Here is an article about inventor Xiaojing Michael Wang:

Title: Unveiling the Innovations of Xiaojing Michael Wang - Pioneering the Fight Against Viral Infections

Introduction:

Xiaojing Michael Wang, a distinguished inventor based in Livermore, CA (US), has made significant strides in the realm of pharmaceutical innovations with a focus on combating viral infections. With an impressive portfolio of 10 patents to his credit, Wang's groundbreaking research has the potential to revolutionize the field of antiviral therapeutics.

Latest Patents:

1. 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives: Wang's invention introduces compounds of Formula (I) for the inhibition of orthomyxovirus replication to treat influenza, offering novel avenues for combating viral disorders.

2. Antiviral pyridopyrazinedione compounds: Wang's patent presents compounds of Formula (I) for treating viral infections caused by herpesviruses, showcasing his innovative approach towards addressing infectious diseases on multiple fronts.

Career Highlights:

Xiaojing Michael Wang has lent his expertise to renowned companies such as Novartis AG and Cell Pathways, where his contributions have propelled advancements in antiviral research and drug development. Wang's dedication to innovation and scientific excellence has positioned him as a key figure in the pharmaceutical industry.

Collaborations:

Wang has collaborated closely with esteemed professionals in the field, including Daniel J Poon and Jeffrey T Bagdanoff. Through synergistic teamwork and shared expertise, Wang and his colleagues have fostered a dynamic environment for cutting-edge research and development.

Conclusion:

In conclusion, Xiaojing Michael Wang's trailblazing inventions underscore his unwavering commitment to advancing antiviral therapeutics and improving health outcomes worldwide. His remarkable journey as an inventor continues to inspire innovation in the fight against infectious diseases, setting a new standard for pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.